Key Events This Week
1 June: Stock opens strong at Rs.39.00 (+5.32%) amid broad market weakness
2 June: Continued gains with Rs.40.67 close (+4.28%) as volume picks up
3 June: Sharp rally to Rs.44.49 (+9.39%) despite Sensex dip
4 June: New 52-week high of Rs.53.38 reached; Q4 FY26 results reveal mounting losses
5 June: Profit-taking leads to Rs.45.73 close (-10.44%) on lower volume

Broad-Based Technical Strength Lifts Parmax Pharma Ltd to 52-Week High of Rs 59.32
2026-06-12 09:47:39With a decisive surge to Rs 59.32 on 12 Jun 2026, Parmax Pharma Ltd has reached a new 52-week high, marking a remarkable 162% increase from its low of Rs 22.6 over the past year. This rally is underpinned by a strong alignment of technical indicators and sustained price momentum, setting the stock apart in a market where the Sensex remains below its 50-day moving average.
Read full news article
Broad-Based Technical Strength Lifts Parmax Pharma Ltd to 52-Week High of Rs 56.5
2026-06-11 09:43:04Surging to a fresh 52-week high of Rs 56.5 on 11 Jun 2026, Parmax Pharma Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a bearish backdrop for the Sensex.
Read full news article
Broad-Based Technical Strength Lifts Parmax Pharma Ltd to 52-Week High of Rs 53.81
2026-06-10 09:45:13With a decisive 5% gap-up opening and a sustained rally to Rs 53.81, Parmax Pharma Ltd has surged to a fresh 52-week high, marking a 41.64% gain over the past year against a declining Sensex. This technical breakout underscores a strong momentum phase for the micro-cap pharmaceutical player.
Read full news article
Parmax Pharma Q4 FY26: Mounting Losses Signal Deepening Crisis
2026-06-04 09:53:10Parmax Pharma Ltd., a micro-cap pharmaceutical company specialising in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO), reported a net loss of ₹0.58 crores for Q4 FY26 (Jan-Mar'26), marking the seventh consecutive quarter of losses. Whilst the loss narrowed sequentially from ₹0.73 crores in Q3 FY26, it remains significantly lower than the ₹1.49 crores loss in Q4 FY25. The company's shares surged 16.88% to ₹52.00 following the results, despite the troubling financial performance, suggesting speculative trading rather than fundamental improvement.
Read full news article
Broad-Based Technical Strength Lifts Parmax Pharma Ltd to 52-Week High of Rs 53.38
2026-06-04 09:50:31With a surge to Rs 53.38 on 4 Jun 2026, Parmax Pharma Ltd has reached a fresh 52-week high, propelled by a striking alignment of technical indicators and sustained price momentum that outpaces its sector and the broader market.
Read full news article








